-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on June 2 A few days ago, Jiangsu Province, a major medical province, issued the "Implementation Plan for the Appraisal of Rational Use of Drugs in Medical Institutions in Jiangsu Province", which detailed various drug use assessment indicators.
The assessment content includes: pharmacy technicians, use of antibacterial drugs, and Management, anti-tumor drug use and management, key monitoring of drug use and management, essential drug use and management, special drug management, drug costs and other related indicators.
Among them, the classification management system and catalog of anti-tumor drugs, the target detection rate of targeted drugs; the proportion of the number of basic drugs purchased, the proportion of essential drug prescriptions for outpatients, and the use rate of essential drugs for inpatients are listed as the focus of the assessment.
The assessment content includes: pharmacy technicians, use of antibacterial drugs, and Management, anti-tumor drug use and management, key monitoring of drug use and management, essential drug use and management, special drug management, drug costs and other related indicators.
Among them, the classification management system and catalog of anti-tumor drugs, the target detection rate of targeted drugs; the proportion of the number of basic drugs purchased, the proportion of essential drug prescriptions for outpatients, and the use rate of essential drugs for inpatients are listed as the focus of the assessment.
Special prescription reviews for11 types of key drugs
Specific to the assessment of rational drug use, hospitals at all levels must meet a series of requirements to get a score.
Jiangsu requires that specific drugs, such as national essential drugs, blood products, Chinese medicine injections, parenteral nutrition preparations, formula foods for special medical purposes, antibacterial drugs, key monitoring drugs, hormones, off-label drugs, tumor drugs, and perioperative drugs, etc.
Carry out special prescription review work.
Jiangsu requires that specific drugs, such as national essential drugs, blood products, Chinese medicine injections, parenteral nutrition preparations, formula foods for special medical purposes, antibacterial drugs, key monitoring drugs, hormones, off-label drugs, tumor drugs, and perioperative drugs, etc.
Carry out special prescription review work.
For anti-cancer drugs, it is necessary to have an anti-cancer drug grading management system and catalog, and specify the conditions for doctors who prescribe the right to prescribe anti-cancer drugs at the restricted use level and the general use level, and the target detection rate of targeted drugs is ≥90%.
For essential medicines, the number of items purchased has increased compared with the previous year, the proportion of prescriptions for essential medicines for outpatients, and the use rate of essential medicines for inpatients will also gradually increase.
For essential medicines, the number of items purchased has increased compared with the previous year, the proportion of prescriptions for essential medicines for outpatients, and the use rate of essential medicines for inpatients will also gradually increase.
In addition, the proportion of the amount used for the bid-winning drugs in the centralized procurement of drugs organized by the state shall be increased by ≥1% compared with the previous year, and drugs shall be timely equipped with national medical insurance negotiation access.
Among antibacterial drugs, the proportion of special-use antibacterial drugs used needs to be reduced year by year.
Key monitoring of drug use and management Establish a full-process management system for key monitoring drugs, establish a list of key monitoring drugs of this institution, and make dynamic adjustments according to changes in the provincial catalog.
Among antibacterial drugs, the proportion of special-use antibacterial drugs used needs to be reduced year by year.
Key monitoring of drug use and management Establish a full-process management system for key monitoring drugs, establish a list of key monitoring drugs of this institution, and make dynamic adjustments according to changes in the provincial catalog.
According to Jiangsu requirements, the assessment scope covers general hospitals, specialist hospitals and primary medical institutions (excluding Chinese medicine hospitals) above the level of the province.
In 2021, with districts and cities as the unit, the assessment coverage of primary medical institutions, secondary medical institutions and tertiary medical institutions will reach 10%, 30% and 100% respectively; by 2022, primary medical institutions and secondary medical institutions The assessment coverage rate will reach 20% and 50% respectively; by 2023, the assessment coverage of secondary medical institutions will be fully covered, and the assessment coverage rate of primary medical institutions will reach more than 50% and increase year by year.
In 2021, with districts and cities as the unit, the assessment coverage of primary medical institutions, secondary medical institutions and tertiary medical institutions will reach 10%, 30% and 100% respectively; by 2022, primary medical institutions and secondary medical institutions The assessment coverage rate will reach 20% and 50% respectively; by 2023, the assessment coverage of secondary medical institutions will be fully covered, and the assessment coverage rate of primary medical institutions will reach more than 50% and increase year by year.
It is understood that the assessment results will be divided into four levels: excellent, good, qualified, and unqualified.
According to the score, the score ≥90 points is excellent, the score ≥80 points and <90 points are good, the score ≥70 points and <80 points are qualified, and the score <70 points are unqualified.
Medical institutions that have major safety hazards in the annual rational use of drugs or drug safety incidents due to medication errors are directly judged as unqualified by the assessment results of the year.
Those who fail the appraisal shall be ordered to make corrections within a time limit, and those who fail to make corrections within the time limit or continuously fail to pass shall be dealt with in accordance with laws, regulations and disciplines.
According to the score, the score ≥90 points is excellent, the score ≥80 points and <90 points are good, the score ≥70 points and <80 points are qualified, and the score <70 points are unqualified.
Medical institutions that have major safety hazards in the annual rational use of drugs or drug safety incidents due to medication errors are directly judged as unqualified by the assessment results of the year.
Those who fail the appraisal shall be ordered to make corrections within a time limit, and those who fail to make corrections within the time limit or continuously fail to pass shall be dealt with in accordance with laws, regulations and disciplines.
Jiangsu also made it clear that it hopes to gradually establish a relatively complete system for the assessment of rational drug use in medical institutions through the assessment work, revise and improve the assessment index system, and achieve standardized management and evaluation of the entire process of drug selection, procurement, supply, storage, and clinical use in medical institutions.
The 3- year critical period for the rational drug use test
Promoting the rational use of medicines in medical institutions is an important measure to continuously deepen the reform of the medical and health system and solve the problem of expensive medical care.
In recent years, the level of rational drug use in my country has gradually improved, but some local medical institutions still need to improve the mechanism of restricting irrational drug use.
Strengthening the management of pharmaceutical affairs in medical institutions and promoting the rational use of drugs have become the focus of current work.
In recent years, the level of rational drug use in my country has gradually improved, but some local medical institutions still need to improve the mechanism of restricting irrational drug use.
Strengthening the management of pharmaceutical affairs in medical institutions and promoting the rational use of drugs have become the focus of current work.
At the end of 2019, the National Health Commission issued a notice on the assessment of the rational use of drugs in medical institutions, and various localities have successively issued landing documents.
A few days ago, Liaoning also proposed that by the end of 2021, all medical institutions above the second level in the province will include the rational use of drugs, prescription review results and other related indicators into the clinician performance evaluation index system, and the corresponding performance evaluation results will be used as important indicators for job appointments.
A few days ago, Liaoning also proposed that by the end of 2021, all medical institutions above the second level in the province will include the rational use of drugs, prescription review results and other related indicators into the clinician performance evaluation index system, and the corresponding performance evaluation results will be used as important indicators for job appointments.
According to the policies of each province, starting from 2021, a three-year periodical assessment of the rational use of drugs in medical institutions will be officially launched.
Some people in the industry believe that with the continuous advancement of the "three-medicine linkage" reform, the assessment of the proportion of medicines has faded out, and the assessment of rational use of medicines will be replaced.
Some people in the industry believe that with the continuous advancement of the "three-medicine linkage" reform, the assessment of the proportion of medicines has faded out, and the assessment of rational use of medicines will be replaced.
Focus on the special treatment of standardized tumor diagnosis and treatment
Non-compliance or heavy fines
The inclusion of anti-tumor drugs in the assessment focus has caused great concern in the industry.
In recent years, the domestic anti-tumor drug market has maintained a fairly high growth rate.
According to data from Meinenet, the sales scale of terminal anti-tumor drugs in China's public medical institutions has increased rapidly, with growth rates of 12.
44%, 16.
36%, 19.
10%, and 21.
30% in 2016-2019, respectively.
Benefiting from the joint drive of medical insurance negotiation policies and newly listed products, the sales of anti-tumor and immunomodulators in 2020 increased by 7.
4% compared with 2019, which is the only major category of chemical drugs with positive year-on-year growth.
In recent years, the domestic anti-tumor drug market has maintained a fairly high growth rate.
According to data from Meinenet, the sales scale of terminal anti-tumor drugs in China's public medical institutions has increased rapidly, with growth rates of 12.
44%, 16.
36%, 19.
10%, and 21.
30% in 2016-2019, respectively.
Benefiting from the joint drive of medical insurance negotiation policies and newly listed products, the sales of anti-tumor and immunomodulators in 2020 increased by 7.
4% compared with 2019, which is the only major category of chemical drugs with positive year-on-year growth.
Behind the rapid growth, there are still objective problems such as the non-standard use of cancer treatment drugs, over-indications and over-guided drugs.
At the end of 2020, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)", according to the current actual situation of oncology drugs in hospitals, implementing drug classification management, emphasizing the evidence-based use of drugs, and emphasizing the standard formulation of drug treatment plans.
Clarified regulatory measures.
At the end of 2020, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)", according to the current actual situation of oncology drugs in hospitals, implementing drug classification management, emphasizing the evidence-based use of drugs, and emphasizing the standard formulation of drug treatment plans.
Clarified regulatory measures.
In April of this year, as the "reported tumor treatment incident" continued to ferment, discussions on the rational use of tumor drugs surged.
Not long ago, the Shanghai Municipal Health Commission announced the administrative sanctions for the doctors involved.
The result of the punishment was a warning and a fine of 30,000 yuan, and the practice was suspended for 6 months.
Shanghai Jiakang Bioengineering Co.
, Ltd.
, which performed NK cell immunotherapy, was fined 1.
65 million yuan for practicing without obtaining a medical institution's practice license.
Not long ago, the Shanghai Municipal Health Commission announced the administrative sanctions for the doctors involved.
The result of the punishment was a warning and a fine of 30,000 yuan, and the practice was suspended for 6 months.
Shanghai Jiakang Bioengineering Co.
, Ltd.
, which performed NK cell immunotherapy, was fined 1.
65 million yuan for practicing without obtaining a medical institution's practice license.
It is understood that the National Health Commission has also taken a series of measures to continuously strengthen the standardized diagnosis and treatment of cancer by strengthening the construction of the cancer diagnosis and treatment system, formulating and improving technical specifications, strengthening the management of cancer medication, carrying out the quality control of cancer diagnosis and treatment, and promoting the application of new treatment technologies.
.
In the next step, the National Health Commission will focus on the standardized diagnosis and treatment of tumors to carry out special treatments.
From the perspective of the industry, the clinical application of anti-tumor drugs is expected to be further regulated.
.
In the next step, the National Health Commission will focus on the standardized diagnosis and treatment of tumors to carry out special treatments.
From the perspective of the industry, the clinical application of anti-tumor drugs is expected to be further regulated.
270 new varieties of basic medicines will be added ?
Another new policy for basic medicines that has attracted much attention has also affected the nerves of the industry.
Since the beginning of this year, news of the basic medicine system and basic medicine catalogue adjustments have continued.
The National Pharmaceutical Policy Work Conference in 2021 made it clear that one of the key tasks this year is to fully promote the implementation of the essential medicine system and optimize and adjust the national essential medicine list.
The "Long-term Prescription Management Regulations (Trial Draft for Soliciting Comments)" issued by the National Health Commission also mentioned that medical institutions should give priority to national basic drugs and other drugs when issuing long-term prescriptions.
Since the beginning of this year, news of the basic medicine system and basic medicine catalogue adjustments have continued.
The National Pharmaceutical Policy Work Conference in 2021 made it clear that one of the key tasks this year is to fully promote the implementation of the essential medicine system and optimize and adjust the national essential medicine list.
The "Long-term Prescription Management Regulations (Trial Draft for Soliciting Comments)" issued by the National Health Commission also mentioned that medical institutions should give priority to national basic drugs and other drugs when issuing long-term prescriptions.
Recently, news has shown that the first draft for the adjustment of the basic medicine catalogue has been solicited in a small range, and the adjustment of the 2021 edition of the basic medicine catalogue will be completed in September.
There is also news that 270 new basic medicines are expected to be added, including 130 chemical medicines and 140 Chinese patent medicines.
If the news is accurate, the list of essential medicines may burst out to a thousand orders of magnitude.
There is also news that 270 new basic medicines are expected to be added, including 130 chemical medicines and 140 Chinese patent medicines.
If the news is accurate, the list of essential medicines may burst out to a thousand orders of magnitude.
However, according to the requirements of the "986 Policy", the proportion of basic medicines in all levels of hospitals must reach: 90% for primary care, 80% for secondary hospitals, and 60% for tertiary hospitals.
At present, there is still a certain gap between the proportion of basic medicines in hospitals at all levels across the country.
According to the performance evaluation results of the national tertiary public hospitals in 2019 notified by the National Health Commission on March 30, although the proportion of essential medicines purchased has increased slightly year-on-year, it has not reached the 60% requirement.
At present, there is still a certain gap between the proportion of basic medicines in hospitals at all levels across the country.
According to the performance evaluation results of the national tertiary public hospitals in 2019 notified by the National Health Commission on March 30, although the proportion of essential medicines purchased has increased slightly year-on-year, it has not reached the 60% requirement.
It is believed that with the implementation of the new edition of the basic medicine catalogue, the "986 policy" and the "1+X" medication model, the basic medicine market will usher in a new scene.
Insiders said that the list of essential medicines may be adjusted in several directions: One is to add proprietary Chinese medicines.
In recent years, the popularity of traditional Chinese medicine has been increasing.
After the new crown epidemic, the call for traditional Chinese medicine has become stronger; the second is to supplement drugs with better clinical effects and fewer side effects ; third , the drugs that are clinically necessary, effective, and expensive, such as anti-inflammatory drugs.
Oncology drugs, especially those drugs whose prices are drastically reduced due to volume purchases and price negotiations; fourth are drugs for chronic diseases with large clinical use and high recognition; fifth, children's drugs, etc.
Insiders said that the list of essential medicines may be adjusted in several directions: One is to add proprietary Chinese medicines.
In recent years, the popularity of traditional Chinese medicine has been increasing.
After the new crown epidemic, the call for traditional Chinese medicine has become stronger; the second is to supplement drugs with better clinical effects and fewer side effects ; third , the drugs that are clinically necessary, effective, and expensive, such as anti-inflammatory drugs.
Oncology drugs, especially those drugs whose prices are drastically reduced due to volume purchases and price negotiations; fourth are drugs for chronic diseases with large clinical use and high recognition; fifth, children's drugs, etc.
The aforementioned industry insiders also believe that since the normalization of mass procurement, the cost of developing large hospitals has become higher and higher, and the primary market and basic drugs have received more attention.
In the future, basic drugs may become a point of contention.
In the future, basic drugs may become a point of contention.
Medical Network News on June 2 A few days ago, Jiangsu Province, a major medical province, issued the "Implementation Plan for the Appraisal of Rational Use of Drugs in Medical Institutions in Jiangsu Province", which detailed various drug use assessment indicators.
The assessment content includes: pharmacy technicians, use of antibacterial drugs, and Management, anti-tumor drug use and management, key monitoring of drug use and management, essential drug use and management, special drug management, drug costs and other related indicators.
Among them, the classification management system and catalog of anti-tumor drugs, the target detection rate of targeted drugs; the proportion of the number of basic drugs purchased, the proportion of essential drug prescriptions for outpatients, and the use rate of essential drugs for inpatients are listed as the focus of the assessment.
The assessment content includes: pharmacy technicians, use of antibacterial drugs, and Management, anti-tumor drug use and management, key monitoring of drug use and management, essential drug use and management, special drug management, drug costs and other related indicators.
Among them, the classification management system and catalog of anti-tumor drugs, the target detection rate of targeted drugs; the proportion of the number of basic drugs purchased, the proportion of essential drug prescriptions for outpatients, and the use rate of essential drugs for inpatients are listed as the focus of the assessment.
Special prescription reviews for 11 types of key drugs
Specific to the assessment of rational drug use, hospitals at all levels must meet a series of requirements to get a score.
Jiangsu requires that specific drugs, such as national essential drugs, blood products, Chinese medicine injections, parenteral nutrition preparations, formula foods for special medical purposes, antibacterial drugs, key monitoring drugs, hormones, off-label drugs, tumor drugs, and perioperative drugs, etc.
Carry out special prescription review work.
Jiangsu requires that specific drugs, such as national essential drugs, blood products, Chinese medicine injections, parenteral nutrition preparations, formula foods for special medical purposes, antibacterial drugs, key monitoring drugs, hormones, off-label drugs, tumor drugs, and perioperative drugs, etc.
Carry out special prescription review work.
For anti-cancer drugs, it is necessary to have an anti-cancer drug grading management system and catalog, and specify the conditions for doctors who prescribe the right to prescribe anti-cancer drugs at the restricted use level and the general use level, and the target detection rate of targeted drugs is ≥90%.
For essential medicines, the number of items purchased has increased compared with the previous year, the proportion of prescriptions for essential medicines for outpatients, and the use rate of essential medicines for inpatients will also gradually increase.
For essential medicines, the number of items purchased has increased compared with the previous year, the proportion of prescriptions for essential medicines for outpatients, and the use rate of essential medicines for inpatients will also gradually increase.
In addition, the proportion of the amount used for the bid-winning drugs in the centralized procurement of drugs organized by the state shall be increased by ≥1% compared with the previous year, and drugs shall be timely equipped with national medical insurance negotiation access.
Among antibacterial drugs, the proportion of special-use antibacterial drugs used needs to be reduced year by year.
Key monitoring of drug use and management Establish a full-process management system for key monitoring drugs, establish a list of key monitoring drugs of this institution, and make dynamic adjustments according to changes in the provincial catalog.
Among antibacterial drugs, the proportion of special-use antibacterial drugs used needs to be reduced year by year.
Key monitoring of drug use and management Establish a full-process management system for key monitoring drugs, establish a list of key monitoring drugs of this institution, and make dynamic adjustments according to changes in the provincial catalog.
According to Jiangsu requirements, the assessment scope covers general hospitals, specialist hospitals and primary medical institutions (excluding Chinese medicine hospitals) above the level of the province.
In 2021, with districts and cities as the unit, the assessment coverage of primary medical institutions, secondary medical institutions and tertiary medical institutions will reach 10%, 30% and 100% respectively; by 2022, primary medical institutions and secondary medical institutions The assessment coverage rate will reach 20% and 50% respectively; by 2023, the assessment coverage of secondary medical institutions will be fully covered, and the assessment coverage rate of primary medical institutions will reach more than 50% and increase year by year.
In 2021, with districts and cities as the unit, the assessment coverage of primary medical institutions, secondary medical institutions and tertiary medical institutions will reach 10%, 30% and 100% respectively; by 2022, primary medical institutions and secondary medical institutions The assessment coverage rate will reach 20% and 50% respectively; by 2023, the assessment coverage of secondary medical institutions will be fully covered, and the assessment coverage rate of primary medical institutions will reach more than 50% and increase year by year.
It is understood that the assessment results will be divided into four levels: excellent, good, qualified, and unqualified.
According to the score, the score ≥90 points is excellent, the score ≥80 points and <90 points are good, the score ≥70 points and <80 points are qualified, and the score <70 points are unqualified.
Medical institutions that have major safety hazards in the annual rational use of drugs or drug safety incidents due to medication errors are directly judged as unqualified by the assessment results of the year.
Those who fail the appraisal shall be ordered to make corrections within a time limit, and those who fail to make corrections within the time limit or continuously fail to pass shall be dealt with in accordance with laws, regulations and disciplines.
According to the score, the score ≥90 points is excellent, the score ≥80 points and <90 points are good, the score ≥70 points and <80 points are qualified, and the score <70 points are unqualified.
Medical institutions that have major safety hazards in the annual rational use of drugs or drug safety incidents due to medication errors are directly judged as unqualified by the assessment results of the year.
Those who fail the appraisal shall be ordered to make corrections within a time limit, and those who fail to make corrections within the time limit or continuously fail to pass shall be dealt with in accordance with laws, regulations and disciplines.
Jiangsu also made it clear that it hopes to gradually establish a relatively complete system for the assessment of rational drug use in medical institutions through the assessment work, revise and improve the assessment index system, and achieve standardized management and evaluation of the entire process of drug selection, procurement, supply, storage, and clinical use in medical institutions.
The 3- year critical period for the rational drug use test
Promoting the rational use of medicines in medical institutions is an important measure to continuously deepen the reform of the medical and health system and solve the problem of expensive medical care.
In recent years, the level of rational drug use in my country has gradually improved, but some local medical institutions still need to improve the mechanism of restricting irrational drug use.
Strengthening the management of pharmaceutical affairs in medical institutions and promoting the rational use of drugs have become the focus of current work.
In recent years, the level of rational drug use in my country has gradually improved, but some local medical institutions still need to improve the mechanism of restricting irrational drug use.
Strengthening the management of pharmaceutical affairs in medical institutions and promoting the rational use of drugs have become the focus of current work.
At the end of 2019, the National Health Commission issued a notice on the assessment of the rational use of drugs in medical institutions, and various localities have successively issued landing documents.
A few days ago, Liaoning also proposed that by the end of 2021, all medical institutions above the second level in the province will include the rational use of drugs, prescription review results and other related indicators into the clinician performance evaluation index system, and the corresponding performance evaluation results will be used as important indicators for job appointments.
A few days ago, Liaoning also proposed that by the end of 2021, all medical institutions above the second level in the province will include the rational use of drugs, prescription review results and other related indicators into the clinician performance evaluation index system, and the corresponding performance evaluation results will be used as important indicators for job appointments.
According to the policies of each province, starting from 2021, a three-year periodical assessment of the rational use of drugs in medical institutions will be officially launched.
Some people in the industry believe that with the continuous advancement of the "three-medicine linkage" reform, the assessment of the proportion of medicines has faded out, and the assessment of rational use of medicines will be replaced.
Some people in the industry believe that with the continuous advancement of the "three-medicine linkage" reform, the assessment of the proportion of medicines has faded out, and the assessment of rational use of medicines will be replaced.
Focus on the special treatment of standardized tumor diagnosis and treatment
Non-compliance or heavy fines
The inclusion of anti-tumor drugs in the assessment focus has caused great concern in the industry.
In recent years, the domestic anti-tumor drug market has maintained a fairly high growth rate.
According to data from Meinenet, the sales scale of terminal anti-tumor drugs in China's public medical institutions has increased rapidly, with growth rates of 12.
44%, 16.
36%, 19.
10%, and 21.
30% in 2016-2019, respectively.
Benefiting from the joint drive of medical insurance negotiation policies and newly listed products, the sales of anti-tumor and immunomodulators in 2020 increased by 7.
4% compared with 2019, which is the only major category of chemical drugs with positive year-on-year growth.
In recent years, the domestic anti-tumor drug market has maintained a fairly high growth rate.
According to data from Meinenet, the sales scale of terminal anti-tumor drugs in China's public medical institutions has increased rapidly, with growth rates of 12.
44%, 16.
36%, 19.
10%, and 21.
30% in 2016-2019, respectively.
Benefiting from the joint drive of medical insurance negotiation policies and newly listed products, the sales of anti-tumor and immunomodulators in 2020 increased by 7.
4% compared with 2019, which is the only major category of chemical drugs with positive year-on-year growth.
Behind the rapid growth, there are still objective problems such as the non-standard use of cancer treatment drugs, over-indications and over-guided drugs.
At the end of 2020, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)", according to the current actual situation of oncology drugs in hospitals, implementing drug classification management, emphasizing the evidence-based use of drugs, and emphasizing the standard formulation of drug treatment plans.
Clarified regulatory measures.
At the end of 2020, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)", according to the current actual situation of oncology drugs in hospitals, implementing drug classification management, emphasizing the evidence-based use of drugs, and emphasizing the standard formulation of drug treatment plans.
Clarified regulatory measures.
In April of this year, as the "reported tumor treatment incident" continued to ferment, discussions on the rational use of tumor drugs surged.
Not long ago, the Shanghai Municipal Health Commission announced the administrative sanctions for the doctors involved.
The result of the punishment was a warning and a fine of 30,000 yuan, and the practice was suspended for 6 months.
Shanghai Jiakang Bioengineering Co.
, Ltd.
, which performed NK cell immunotherapy, was fined 1.
65 million yuan for practicing without obtaining a medical institution's practice license.
Not long ago, the Shanghai Municipal Health Commission announced the administrative sanctions for the doctors involved.
The result of the punishment was a warning and a fine of 30,000 yuan, and the practice was suspended for 6 months.
Shanghai Jiakang Bioengineering Co.
, Ltd.
, which performed NK cell immunotherapy, was fined 1.
65 million yuan for practicing without obtaining a medical institution's practice license.
It is understood that the National Health Commission has also taken a series of measures to continuously strengthen the standardized diagnosis and treatment of cancer by strengthening the construction of the cancer diagnosis and treatment system, formulating and improving technical specifications, strengthening the management of cancer medication, carrying out the quality control of cancer diagnosis and treatment, and promoting the application of new treatment technologies.
.
In the next step, the National Health Commission will focus on the standardized diagnosis and treatment of tumors to carry out special treatments.
From the perspective of the industry, the clinical application of anti-tumor drugs is expected to be further regulated.
.
In the next step, the National Health Commission will focus on the standardized diagnosis and treatment of tumors to carry out special treatments.
From the perspective of the industry, the clinical application of anti-tumor drugs is expected to be further regulated.
270 new varieties of basic medicines will be added ?
Another new policy for basic medicines that has attracted much attention has also affected the nerves of the industry.
Since the beginning of this year, news of the basic medicine system and basic medicine catalogue adjustments have continued.
The National Pharmaceutical Policy Work Conference in 2021 made it clear that one of the key tasks this year is to fully promote the implementation of the essential medicine system and optimize and adjust the national essential medicine list.
The "Long-term Prescription Management Regulations (Trial Draft for Soliciting Comments)" issued by the National Health Commission also mentioned that medical institutions should give priority to national basic drugs and other drugs when issuing long-term prescriptions.
Since the beginning of this year, news of the basic medicine system and basic medicine catalogue adjustments have continued.
The National Pharmaceutical Policy Work Conference in 2021 made it clear that one of the key tasks this year is to fully promote the implementation of the essential medicine system and optimize and adjust the national essential medicine list.
The "Long-term Prescription Management Regulations (Trial Draft for Soliciting Comments)" issued by the National Health Commission also mentioned that medical institutions should give priority to national basic drugs and other drugs when issuing long-term prescriptions.
Recently, news has shown that the first draft for the adjustment of the basic medicine catalogue has been solicited in a small range, and the adjustment of the 2021 edition of the basic medicine catalogue will be completed in September.
There is also news that 270 new basic medicines are expected to be added, including 130 chemical medicines and 140 Chinese patent medicines.
If the news is accurate, the list of essential medicines may burst out to a thousand orders of magnitude.
There is also news that 270 new basic medicines are expected to be added, including 130 chemical medicines and 140 Chinese patent medicines.
If the news is accurate, the list of essential medicines may burst out to a thousand orders of magnitude.
However, according to the requirements of the "986 Policy", the proportion of basic medicines in all levels of hospitals must reach: 90% for primary care, 80% for secondary hospitals, and 60% for tertiary hospitals.
At present, there is still a certain gap between the proportion of basic medicines in hospitals at all levels across the country.
According to the performance evaluation results of the national tertiary public hospitals in 2019 notified by the National Health Commission on March 30, although the proportion of essential medicines purchased has increased slightly year-on-year, it has not reached the 60% requirement.
At present, there is still a certain gap between the proportion of basic medicines in hospitals at all levels across the country.
According to the performance evaluation results of the national tertiary public hospitals in 2019 notified by the National Health Commission on March 30, although the proportion of essential medicines purchased has increased slightly year-on-year, it has not reached the 60% requirement.
It is believed that with the implementation of the new edition of the basic medicine catalogue, the "986 policy" and the "1+X" medication model, the basic medicine market will usher in a new scene.
Insiders said that the list of essential medicines may be adjusted in several directions: One is to add proprietary Chinese medicines.
In recent years, the popularity of traditional Chinese medicine has been increasing.
After the new crown epidemic, the call for traditional Chinese medicine has become stronger; the second is to supplement drugs with better clinical effects and fewer side effects ; third , the drugs that are clinically necessary, effective, and expensive, such as anti-inflammatory drugs.
Oncology drugs, especially those drugs whose prices are drastically reduced due to volume purchases and price negotiations; fourth are drugs for chronic diseases with large clinical use and high recognition; fifth, children's drugs, etc.
Insiders said that the list of essential medicines may be adjusted in several directions: One is to add proprietary Chinese medicines.
In recent years, the popularity of traditional Chinese medicine has been increasing.
After the new crown epidemic, the call for traditional Chinese medicine has become stronger; the second is to supplement drugs with better clinical effects and fewer side effects ; third , the drugs that are clinically necessary, effective, and expensive, such as anti-inflammatory drugs.
Oncology drugs, especially those drugs whose prices are drastically reduced due to volume purchases and price negotiations; fourth are drugs for chronic diseases with large clinical use and high recognition; fifth, children's drugs, etc.
The aforementioned industry insiders also believe that since the normalization of mass procurement, the cost of developing large hospitals has become higher and higher, and the primary market and basic drugs have received more attention.
In the future, basic drugs may become a point of contention.
In the future, basic drugs may become a point of contention.
Medical Network News on June 2 A few days ago, Jiangsu Province, a major medical province, issued the "Implementation Plan for the Appraisal of Rational Use of Drugs in Medical Institutions in Jiangsu Province", which detailed various drug use assessment indicators.
The assessment content includes: pharmacy technicians, use of antibacterial drugs, and Management, anti-tumor drug use and management, key monitoring of drug use and management, essential drug use and management, special drug management, drug costs and other related indicators.
Among them, the classification management system and catalog of anti-tumor drugs, the target detection rate of targeted drugs; the proportion of the number of basic drugs purchased, the proportion of essential drug prescriptions for outpatients, and the use rate of essential drugs for inpatients are listed as the focus of the assessment.
The assessment content includes: pharmacy technicians, use of antibacterial drugs, and Management, anti-tumor drug use and management, key monitoring of drug use and management, essential drug use and management, special drug management, drug costs and other related indicators.
Among them, the classification management system and catalog of anti-tumor drugs, the target detection rate of targeted drugs; the proportion of the number of basic drugs purchased, the proportion of essential drug prescriptions for outpatients, and the use rate of essential drugs for inpatients are listed as the focus of the assessment.
Special prescription reviews for 11 types of key drugs
Special prescription reviews for 11 types of key drugs Specific to the assessment of rational drug use, hospitals at all levels must meet a series of requirements to get a score.
Jiangsu requires that specific drugs, such as national essential drugs, blood products, Chinese medicine injections, parenteral nutrition preparations, formula foods for special medical purposes, antibacterial drugs, key monitoring drugs, hormones, off-label drugs, tumor drugs, and perioperative drugs, etc.
Carry out special prescription review work.
Jiangsu requires that specific drugs, such as national essential drugs, blood products, Chinese medicine injections, parenteral nutrition preparations, formula foods for special medical purposes, antibacterial drugs, key monitoring drugs, hormones, off-label drugs, tumor drugs, and perioperative drugs, etc.
Carry out special prescription review work.
For anti-cancer drugs, it is necessary to have an anti-cancer drug grading management system and catalog, and specify the conditions for doctors who prescribe the right to prescribe anti-cancer drugs at the restricted use level and the general use level, and the target detection rate of targeted drugs is ≥90%.
For essential medicines, the number of items purchased has increased compared with the previous year, the proportion of prescriptions for essential medicines for outpatients, and the use rate of essential medicines for inpatients will also gradually increase.
For essential medicines, the number of items purchased has increased compared with the previous year, the proportion of prescriptions for essential medicines for outpatients, and the use rate of essential medicines for inpatients will also gradually increase.
In addition, the proportion of the amount used for the bid-winning drugs in the centralized procurement of drugs organized by the state shall be increased by ≥1% compared with the previous year, and drugs shall be timely equipped with national medical insurance negotiation access.
Among antibacterial drugs, the proportion of special-use antibacterial drugs used needs to be reduced year by year.
Key monitoring of drug use and management Establish a full-process management system for key monitoring drugs, establish a list of key monitoring drugs of this institution, and make dynamic adjustments according to changes in the provincial catalog.
Among antibacterial drugs, the proportion of special-use antibacterial drugs used needs to be reduced year by year.
Key monitoring of drug use and management Establish a full-process management system for key monitoring drugs, establish a list of key monitoring drugs of this institution, and make dynamic adjustments according to changes in the provincial catalog.
According to Jiangsu requirements, the assessment scope covers general hospitals, specialist hospitals and primary medical institutions (excluding Chinese medicine hospitals) above the level of the province.
In 2021, with districts and cities as the unit, the assessment coverage of primary medical institutions, secondary medical institutions and tertiary medical institutions will reach 10%, 30% and 100% respectively; by 2022, primary medical institutions and secondary medical institutions The assessment coverage rate will reach 20% and 50% respectively; by 2023, the assessment coverage of secondary medical institutions will be fully covered, and the assessment coverage rate of primary medical institutions will reach more than 50% and increase year by year.
In 2021, with districts and cities as the unit, the assessment coverage of primary medical institutions, secondary medical institutions and tertiary medical institutions will reach 10%, 30% and 100% respectively; by 2022, primary medical institutions and secondary medical institutions The assessment coverage rate will reach 20% and 50% respectively; by 2023, the assessment coverage of secondary medical institutions will be fully covered, and the assessment coverage rate of primary medical institutions will reach more than 50% and increase year by year.
It is understood that the assessment results will be divided into four levels: excellent, good, qualified, and unqualified.
According to the score, the score ≥90 points is excellent, the score ≥80 points and <90 points are good, the score ≥70 points and <80 points are qualified, and the score <70 points are unqualified.
Medical institutions that have major safety hazards in the annual rational use of drugs or drug safety incidents due to medication errors are directly judged as unqualified by the assessment results of the year.
Those who fail the appraisal shall be ordered to make corrections within a time limit, and those who fail to make corrections within the time limit or continuously fail to pass shall be dealt with in accordance with laws, regulations and disciplines.
According to the score, the score ≥90 points is excellent, the score ≥80 points and <90 points are good, the score ≥70 points and <80 points are qualified, and the score <70 points are unqualified.
Medical institutions that have major safety hazards in the annual rational use of drugs or drug safety incidents due to medication errors are directly judged as unqualified by the assessment results of the year.
Those who fail the appraisal shall be ordered to make corrections within a time limit, and those who fail to make corrections within the time limit or continuously fail to pass shall be dealt with in accordance with laws, regulations and disciplines.
Jiangsu also made it clear that it hopes to gradually establish a relatively complete system for the assessment of rational drug use in medical institutions through the assessment work, revise and improve the assessment index system, and achieve standardized management and evaluation of the entire process of drug selection, procurement, supply, storage, and clinical use in medical institutions.
The 3- year critical period for the rational drug use test
The 3- year critical period for the rational drug use test Promoting the rational use of medicines in medical institutions is an important measure to continuously deepen the reform of the medical and health system and solve the problem of expensive medical care.
In recent years, the level of rational drug use in my country has gradually improved, but some local medical institutions still need to improve the mechanism of restricting irrational drug use.
Strengthening the management of pharmaceutical affairs in medical institutions and promoting the rational use of drugs have become the focus of current work.
Medicine Medicine MedicineIn recent years, the level of rational drug use in my country has gradually improved, but some local medical institutions still need to improve the mechanism of restricting irrational drug use.
Strengthening the management of pharmaceutical affairs in medical institutions and promoting the rational use of drugs have become the focus of current work.
At the end of 2019, the National Health Commission issued a notice on the assessment of the rational use of drugs in medical institutions, and various localities have successively issued landing documents.
A few days ago, Liaoning also proposed that by the end of 2021, all medical institutions above the second level in the province will include the rational use of drugs, prescription review results and other related indicators into the clinician performance evaluation index system, and the corresponding performance evaluation results will be used as important indicators for job appointments.
Healthy, healthy, healthyA few days ago, Liaoning also proposed that by the end of 2021, all medical institutions above the second level in the province will include the rational use of drugs, prescription review results and other related indicators into the clinician performance evaluation index system, and the corresponding performance evaluation results will be used as important indicators for job appointments.
According to the policies of each province, starting from 2021, a three-year periodical assessment of the rational use of drugs in medical institutions will be officially launched.
Some people in the industry believe that with the continuous advancement of the "three-medicine linkage" reform, the assessment of the proportion of medicines has faded out, and the assessment of rational use of medicines will be replaced.
Some people in the industry believe that with the continuous advancement of the "three-medicine linkage" reform, the assessment of the proportion of medicines has faded out, and the assessment of rational use of medicines will be replaced.
Focus on the special treatment of standardized tumor diagnosis and treatment
Focus on the special treatment of standardized tumor diagnosis and treatment Non-compliance or heavy fines
Non-compliance or heavy fines The inclusion of anti-tumor drugs in the assessment focus has caused great concern in the industry.
In recent years, the domestic anti-tumor drug market has maintained a fairly high growth rate.
According to data from Meinenet, the sales scale of terminal anti-tumor drugs in China's public medical institutions has increased rapidly, with growth rates of 12.
44%, 16.
36%, 19.
10%, and 21.
30% in 2016-2019, respectively.
Benefiting from the joint drive of medical insurance negotiation policies and newly listed products, the sales of anti-tumor and immunomodulators in 2020 increased by 7.
4% compared with 2019, which is the only major category of chemical drugs with positive year-on-year growth.
In recent years, the domestic anti-tumor drug market has maintained a fairly high growth rate.
According to data from Meinenet, the sales scale of terminal anti-tumor drugs in China's public medical institutions has increased rapidly, with growth rates of 12.
44%, 16.
36%, 19.
10%, and 21.
30% in 2016-2019, respectively.
Benefiting from the joint drive of medical insurance negotiation policies and newly listed products, the sales of anti-tumor and immunomodulators in 2020 increased by 7.
4% compared with 2019, which is the only major category of chemical drugs with positive year-on-year growth.
Behind the rapid growth, there are still objective problems such as the non-standard use of cancer treatment drugs, over-indications and over-guided drugs.
At the end of 2020, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)", according to the current actual situation of oncology drugs in hospitals, implementing drug classification management, emphasizing the evidence-based use of drugs, and emphasizing the standard formulation of drug treatment plans.
Clarified regulatory measures.
At the end of 2020, the National Health Commission issued the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)", according to the current actual situation of oncology drugs in hospitals, implementing drug classification management, emphasizing the evidence-based use of drugs, and emphasizing the standard formulation of drug treatment plans.
Clarified regulatory measures.
In April of this year, as the "reported tumor treatment incident" continued to ferment, discussions on the rational use of tumor drugs surged.
Not long ago, the Shanghai Municipal Health Commission announced the administrative sanctions for the doctors involved.
The result of the punishment was a warning and a fine of 30,000 yuan, and the practice was suspended for 6 months.
Shanghai Jiakang Bioengineering Co.
, Ltd.
, which performed NK cell immunotherapy, was fined 1.
65 million yuan for practicing without obtaining a medical institution's practice license.
Not long ago, the Shanghai Municipal Health Commission announced the administrative sanctions for the doctors involved.
The result of the punishment was a warning and a fine of 30,000 yuan, and the practice was suspended for 6 months.
Shanghai Jiakang Bioengineering Co.
, Ltd.
, which performed NK cell immunotherapy, was fined 1.
65 million yuan for practicing without obtaining a medical institution's practice license.
It is understood that the National Health Commission has also taken a series of measures to continuously strengthen the standardized diagnosis and treatment of cancer by strengthening the construction of the cancer diagnosis and treatment system, formulating and improving technical specifications, strengthening the management of cancer medication, carrying out the quality control of cancer diagnosis and treatment, and promoting the application of new treatment technologies.
.
In the next step, the National Health Commission will focus on the standardized diagnosis and treatment of tumors to carry out special treatments.
From the perspective of the industry, the clinical application of anti-tumor drugs is expected to be further regulated.
.
In the next step, the National Health Commission will focus on the standardized diagnosis and treatment of tumors to carry out special treatments.
From the perspective of the industry, the clinical application of anti-tumor drugs is expected to be further regulated.
270 new varieties of basic medicines will be added ?
270 new varieties of basic medicines will be added ? Another new policy for basic medicines that has attracted much attention has also affected the nerves of the industry.
Since the beginning of this year, news of the basic medicine system and basic medicine catalogue adjustments have continued.
The National Pharmaceutical Policy Work Conference in 2021 made it clear that one of the key tasks this year is to fully promote the implementation of the essential medicine system and optimize and adjust the national essential medicine list.
The "Long-term Prescription Management Regulations (Trial Draft for Soliciting Comments)" issued by the National Health Commission also mentioned that medical institutions should give priority to national basic drugs and other drugs when issuing long-term prescriptions.
Since the beginning of this year, news of the basic medicine system and basic medicine catalogue adjustments have continued.
The National Pharmaceutical Policy Work Conference in 2021 made it clear that one of the key tasks this year is to fully promote the implementation of the essential medicine system and optimize and adjust the national essential medicine list.
The "Long-term Prescription Management Regulations (Trial Draft for Soliciting Comments)" issued by the National Health Commission also mentioned that medical institutions should give priority to national basic drugs and other drugs when issuing long-term prescriptions.
Recently, news has shown that the first draft for the adjustment of the basic medicine catalogue has been solicited in a small range, and the adjustment of the 2021 edition of the basic medicine catalogue will be completed in September.
There is also news that 270 new basic medicines are expected to be added, including 130 chemical medicines and 140 Chinese patent medicines.
If the news is accurate, the list of essential medicines may burst out to a thousand orders of magnitude.
There is also news that 270 new basic medicines are expected to be added, including 130 chemical medicines and 140 Chinese patent medicines.
If the news is accurate, the list of essential medicines may burst out to a thousand orders of magnitude.
However, according to the requirements of the "986 Policy", the proportion of basic medicines in all levels of hospitals must reach: 90% for primary care, 80% for secondary hospitals, and 60% for tertiary hospitals.
At present, there is still a certain gap between the proportion of basic medicines in hospitals at all levels across the country.
According to the performance evaluation results of the national tertiary public hospitals in 2019 notified by the National Health Commission on March 30, although the proportion of essential medicines purchased has increased slightly year-on-year, it has not reached the 60% requirement.
Hospital Hospital Hospital Procurement Procurement ProcurementAt present, there is still a certain gap between the proportion of basic medicines in hospitals at all levels across the country.
According to the performance evaluation results of the national tertiary public hospitals in 2019 notified by the National Health Commission on March 30, although the proportion of essential medicines purchased has increased slightly year-on-year, it has not reached the 60% requirement.
It is believed that with the implementation of the new edition of the basic medicine catalogue, the "986 policy" and the "1+X" medication model, the basic medicine market will usher in a new scene.
Insiders said that the list of essential medicines may be adjusted in several directions: One is to add proprietary Chinese medicines.
In recent years, the popularity of traditional Chinese medicine has been increasing.
After the new crown epidemic, the call for traditional Chinese medicine has become stronger; the second is to supplement drugs with better clinical effects and fewer side effects ; third , the drugs that are clinically necessary, effective, and expensive, such as anti-inflammatory drugs.
Oncology drugs, especially those drugs whose prices are drastically reduced due to volume purchases and price negotiations; fourth are drugs for chronic diseases with large clinical use and high recognition; fifth, children's drugs, etc.
Medicine, medicine, medicineInsiders said that the list of essential medicines may be adjusted in several directions: One is to add proprietary Chinese medicines.
In recent years, the popularity of traditional Chinese medicine has been increasing.
After the new crown epidemic, the call for traditional Chinese medicine has become stronger; the second is to supplement drugs with better clinical effects and fewer side effects ; third , the drugs that are clinically necessary, effective, and expensive, such as anti-inflammatory drugs.
Oncology drugs, especially those drugs whose prices are drastically reduced due to volume purchases and price negotiations; fourth are drugs for chronic diseases with large clinical use and high recognition; fifth, children's drugs, etc.
The aforementioned industry insiders also believe that since the normalization of mass procurement, the cost of developing large hospitals has become higher and higher, and the primary market and basic drugs have received more attention.
In the future, basic drugs may become a point of contention.
In the future, basic drugs may become a point of contention.
